Literature DB >> 11349148

Structural mechanism for statin inhibition of HMG-CoA reductase.

E S Istvan1, J Deisenhofer.   

Abstract

HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGR) catalyzes the committed step in cholesterol biosynthesis. Statins are HMGR inhibitors with inhibition constant values in the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in the treatment of hypercholesterolemia. We have determined structures of the catalytic portion of human HMGR complexed with six different statins. The statins occupy a portion of the binding site of HMG-CoA, thus blocking access of this substrate to the active site. Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes. If these residues were not flexible, they would sterically hinder statin binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349148     DOI: 10.1126/science.1059344

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  325 in total

Review 1.  Statins' benefits begin to sprout.

Authors:  D C Altieri
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 2.  Pharmacologic characteristics of statins.

Authors:  James M McKenney
Journal:  Clin Cardiol       Date:  2003-04       Impact factor: 2.882

Review 3.  Isoprenoids as mediators of the biological effects of statins.

Authors:  James K Liao
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 4.  Comparing HMG-CoA reductase inhibitors.

Authors:  Peter H Jones
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

5.  Inferring functional constraints and divergence in protein families using 3D mapping of phylogenetic information.

Authors:  Christian Blouin; Yan Boucher; Andrew J Roger
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

6.  Purification, crystallization and preliminary X-ray analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase of Streptococcus pneumoniae.

Authors:  Liping Zhang; Lingling Feng; Li Zhou; Jie Gui; Jian Wan; Xiaopeng Hu
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-10-29

7.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

8.  Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.

Authors:  Hye Jin Wang; Jae Yeo Park; Obin Kwon; Eun Yeong Choe; Chul Hoon Kim; Kyu Yeon Hur; Myung-Shik Lee; Mijin Yun; Bong Soo Cha; Young-Bum Kim; Hyangkyu Lee; Eun Seok Kang
Journal:  Autophagy       Date:  2015-11-02       Impact factor: 16.016

Review 9.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

Review 10.  New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?

Authors:  Laura Trapani; Marco Segatto; Valentina Pallottini
Journal:  World J Hepatol       Date:  2013-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.